Searchable abstracts of presentations at key conferences in endocrinology

ea0099p26 | Adrenal and Cardiovascular Endocrinology | ECE2024

Towards precision medicine in adrenocortical carcinoma; predicting response to mitotane using proteomics

Vietor Charlotte , Iyer Anand , van Koetsveld Peter , Dogan-Oruc Fadime , Moradi-Zeyenedpour Lona , Franssen Gaston , Verhoef Cornelis , van Ginhoven Tessa , Luider Theo , Feelders Richard , Hofland Leo

Background: Adrenocortical carcinoma (ACC) is a rare but devastating malignancy (5-year survival 18–57%), with limited treatment options. Currently, mitotane is the first-line medical treatment for metastatic ACC and is used in the adjuvant setting after surgery to prevent recurrence. Mitotane is an adrenolytic drug that is thought to act by disruption of mitochondria with subsequent activation of apoptosis. However, mitotane treatment comes with many drawbacks, such as s...

ea0099rc7.1 | Rapid Communications 7: Endocrine-related Cancer | ECE2024

PRAP study - Partial versus radical adrenalectomy for hereditary pheochromocytomas

Xu Kai , Langenhuijsen Johannes , Vietor Charlotte , Feelders Richard , van Ginhoven Tessa , Elhassan Yasir , Bioletto Fabio , Parasiliticaprino Mirko , Zandee Wouter , Kruijff Schelto , AEkerstrom Tobias , Pamporaki Christina , Bechmann Nicole , Lussey-Lepoutre Charlotte , Canu Letizia , Steenaard Rebecca , Driessens Natacha , Velema Marieke , Dreijerink Koen , Engelsman Anton , Timmers Henri , de Laat Marieke

Introduction: Pheochromocytoma, a rare catecholamine-secreting adrenal tumor, can cause hypertension and life-threatening complications. Hereditary cases have an increased risk of developing bilateral disease. Standard treatment involves radical adrenalectomy, leading to adrenal insufficiency in bilateral cases. Partial adrenalectomy aims to preserve adrenal function but has higher recurrence rates. This study compares outcomes of partial vs radical adrenalectomy in hereditary...